P-0060 First-Line Single Agent Chemotherapy in Recurred or Metastatic Gastric Cancer Patients with Poor Clinical Condition
نویسندگان
چکیده
منابع مشابه
First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status
Combination chemotherapy is a standard treatment approach in advanced gastric cancer. However, combination chemotherapy for advanced gastric cancer is often associated with severe treatment-related toxicities and most oncologists are reluctant to perform combination chemotherapy in patients with a poor clinical condition. We retrospectively investigated the efficacy and tolerability of single-a...
متن کاملPrognostic Factors for First-Line Chemotherapy Treated Metastatic Gastric Cancer
Despite the reduced incidence, gastric cancer is the second most common among cancer-related deaths in the word. In two-third of patients with gastric cancer are diagnosed with metastatic disease (Kamangar et al., 2006; Jemal et al., 2011). Without effective treatment, the median survival for metastatic disease is 3 to 5, however it may be extended 8-12 months with the platinum and taxane-conta...
متن کاملIntroduction. Single-agent or combination chemotherapy in metastatic breast cancer.
It is fair to say that combination chemotherapy is the standard of care in metastatic breast cancer. In many ways, however, the burden of proof that it is the standard of care remains with those who advocate combination therapy. Some of the push to consider combination therapy as the standard is provided by a meta-analysis of trials comparing single-agent and combination therapy in this setting...
متن کاملSingle-Agent or Combination Chemotherapy in Metastatic Breast Cancer
It is fair to say that combination chemotherapy is the standard of care in metastatic breast cancer. In many ways, however, the burden of proof that it is the standard of care remains with those who advocate combination therapy. Some of the push to consider combination therapy as the standard is provided by a meta-analysis of trials comparing single-agent and combination therapy in this setting...
متن کاملClinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
OBJECTIVE To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2- metastatic breast cancer (mBC) patients. METHODS This is a retrospective chart review of 139 postmenopausal HR+/HER2- mBC patients initiating first-line ET monotherapy or CT. Overall survival (OS) was described using Kaplan-Meier...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2012
ISSN: 0923-7534
DOI: 10.1016/s0923-7534(20)30267-2